论文部分内容阅读
[目的]分析FOLFOX方案辅助化疗结直肠癌的疗效、疗效预测因素及毒副反应。[方法]43例根治术后病理确诊为结直肠癌的患者行FOLFOX方案辅助化疗,化疗2～12个周期,中位化疗6个周期。以无病生存期(DFS)、总生存期(OS)、毒副反应作为观察指标,采用Kaplan-Meier法绘制生存曲线。Cox多因素回归分析探讨疗效预测因素。[结果]中位随访22个月,中位DFS24.0个月,2年无病生存率46.6%,3年无病生存率23.3%。2年OS93.3%,3年OS69.7%。Cox回归分析显示DSF的预测因素是肿瘤分期、肿瘤部位、化疗周期数。最常见毒副反应为骨髓抑制、胃肠道反应、周围神经毒性。[结论]FOLFOX方案用于结直肠癌辅助化疗疗效较好,毒副反应可以耐受。化疗周期数是影响疗效的可能因素。
[Objective] To analyze the curative effect, predictors of efficacy and side effects of FOLFOX adjuvant chemotherapy for colorectal cancer. [Method] Forty-three patients with pathologically diagnosed colorectal cancer underwent FOLFOX regimen adjuvant chemotherapy with 2 to 12 cycles of chemotherapy and 6 cycles of median chemotherapy. Survival curves were calculated by Kaplan-Meier method with DFS, OS and adverse reactions as observation indexes. Cox multivariate regression analysis to explore predictors of efficacy. [Results] The median follow-up was 22 months. The median DFS was 24.0 months. The 2-year disease-free survival rate was 46.6% and the 3-year disease-free survival rate was 23.3%. OS93.3% for 2 years and OS69.7% for 3 years. Cox regression analysis showed that the predictor of DSF was tumor stage, tumor site, and the number of chemotherapy cycles. The most common side effects of bone marrow suppression, gastrointestinal reactions, peripheral neurotoxicity. [Conclusion] The FOLFOX regimen is effective in adjuvant chemotherapy of colorectal cancer, and the toxic side effects can be tolerated. The number of cycles of chemotherapy is a potential contributor to efficacy.